DNA sequence polymorphisms in the form of restriction fragment length polymorphisms (RFLPs) 
Step 3. Sequencing of PCR amplified products After treatment of the amplification products from six unrelated subjects with Klenow fragment polymerase and polynucleotide kinase, the fragments from each subject are cloned into SmaI cut, alkaline phosphatase treated, Ml 3 vector. After transformation, a number of white plaques from each sample are picked into sterile PBS (100 p1), vortexed, and two 3 jl aliquots removed and used to set up two PCR reactions (a and b). Amplifying with one of the original primers and (a) extended normal or (b) extended reverse M13 primers in each tube, the presence and orientation of the insert can be confirmed. The PBS suspension can then be used to inoculate a culture for preparation of single stranded DNA. Six clones in each orientation are then sequenced. The amount of sequencing carried out will depend on the importance of the locus to the operator. However, using rapid protocols, such as the Amersham Multiwell System and sequencing the clone in both directions, the time taken is minimised. Variant sequences identified can then be screened for restriction site alteration using computer mapping. If a potential RFLP is located, it can be confirmed as genuine and not a PCR artefact, by digestion of amplified products from a number of group.bmj.com on October 19, 2017 -Published by http://jmg.bmj.com/ Downloaded from subjects and further characterised as described in step 5. Using this approach, sequencing approximately 400 bp, an RFLP within the N-ras7 gene (original amplification 2000 bp) has been identified. If no polymorphism is detected then a separate region can be amplified and the procedure repeated from step 2 onwards. However, if sequence variants are identified but they do not alter a restriction enzyme recognition sequence then go to step 4.
Step 4. Design of modified primers Sequence variants that do not alter restriction sites can often be used as polymorphisms by designing primers containing mismatches close to the 3' end, which, on amplification, incorporate the polymorphic base into a restriction site (usually the polymorphic base would be the first base 3' to the primer). The polymorphism can then be assayed for by restriction of the PCR product. As the result of this digest will be cleavage of the primer from the product, care should be taken that this will be easily visible on conventional agarose gels (for example, final amplification product 150 to 200 bp). Again, the region can be amplified from a panel of subjects to ascertain correct PCR conditions (which may be critical) and further characterised as described in step 5. Using this approach polymorphisms within the Ha-ras (Hoban et al, unpublished data) and Ki-ras8 genes have been identified.
Step 5. Characterisation of polymorphism New polymorphisms are characterised by determining the allele frequency in a population of 50 unrelated subjects after PCR amplification. Mendelian inheritance is confirmed by characterisation of the polymorphism within families and screening for codominant segregation.
Implications
We feel that by using this or similar strategies it is possible to detect multiple, easily assayed, PCR based polymorphisms within virtually any known gene. The combination of these should lead to high PIC value within the target gene.458 If this proves to be true, then it is probable that within a relatively short time PCR analysis will replace Southern blotting as the major technique in human genetics. The advantage of this strategy over, for example, the search for highly informative dinucleotide repeat polymorphisms is the accuracy with which the polymorphism can be targeted, not just close to a gene of interest but to a particular location within a gene. If the polymorphism is detected in a region of the sequence that is encoded within the mRNA, then using RT-PCR with a cDNA target enables the study of relative expression levels from each parental allele. This approach has been shown to work well for c-Ki-ras, c-Ha-ras, and PRAD1 (unpublished data).
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